EXPERIMENTAL AND MOLECULAR PATHOLOGY, a distinguished journal published by Academic Press Inc Elsevier Science, is recognized for its significant contributions to the fields of pathology, clinical biochemistry, and molecular biology. With an ISSN of 0014-4800 and an E-ISSN of 1096-0945, this journal provides a platform for the dissemination of high-quality research articles, reviews, and experimental studies that deepen our understanding of disease mechanisms and diagnostic pathways. Since its inception in 1962 and through its converged publication years, the journal has consistently maintained a solid impact in the academic community, achieving high Scopus rankings—ranked #15 in the field of Pathology and Forensic Medicine and #22 in Clinical Biochemistry, showcasing a commendable percentile standing of 93rd and 81st respectively in 2023. The journal is accessible through various academic libraries and institutional subscriptions, making it an essential resource for researchers, professionals, and students committed to advancing knowledge in these critical areas. With a categorization that includes Q1 rankings in Pathology and Forensic Medicine, EXPERIMENTAL AND MOLECULAR PATHOLOGY stands as a prominent venue for pioneering scientific inquiry and collaborative advancement in molecular diagnostics and therapeutic strategies.

ANNALS OF NEUROLOGY, published by Wiley, stands as a leading journal in the field of neurology, renowned for its rigorous peer-reviewed articles that contribute significantly to the understanding of neurological disorders and advances in clinical practices. With an impressive impact factor and ranked Q1 in both neurology and clinical neurology categories, this journal positions itself among the top repositories of cutting-edge research, indexed in Scopus with exemplary ranks in the 98th and 97th percentiles respectively. Since its inception in 1977 and with a commitment to excellence extending to 2024 and beyond, ANNALS OF NEUROLOGY aims to disseminate groundbreaking studies and foster dialogue within the academic community, making it an essential resource for researchers, healthcare professionals, and students dedicated to neurology. Although it does not currently offer open access, its accessibility through institutional subscriptions facilitates widespread scholarly engagement.

CELLULAR AND MOLECULAR LIFE SCIENCES, published by SPRINGER BASEL AG, stands as a premier journal dedicated to advancing the field of cellular and molecular biology. With an impressive 2023 impact factor reflected in its Q1 rankings across key categories—including Cell Biology, Molecular Biology, and Pharmacology—it serves as a critical platform for researchers aiming to disseminate high-quality findings in these dynamic fields. Operated under an open access framework, the journal allows broader accessibility to groundbreaking research, fostering collaboration amongst scientists globally. Based in Switzerland, CELLULAR AND MOLECULAR LIFE SCIENCES has been at the forefront of scientific publishing since 1952, adapting to contemporary scientific challenges and trends, ultimately shaping the future of life sciences.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Molecular Brain is a prestigious open-access journal published by BMC, dedicated to advancing the field of neuroscience with a particular focus on cellular and molecular mechanisms. Since its inception in 2008, the journal has been committed to disseminating high-quality research that explores the intricate workings of the brain, particularly in areas related to cellular and molecular neuroscience. Located in the heart of London, England, Molecular Brain has garnered significant recognition in the academic community, boasting a 2023 categorization in the Q2 quartile for both Cellular and Molecular Neuroscience and Molecular Biology, reflecting its growing influence and relevance in these fields. With its Scopus ranks placing it in the top 32% and 38% of its respective categories, the journal serves as an essential platform for researchers, professionals, and students alike, encouraging collaboration and knowledge-sharing through its accessible online format.

Fluids and Barriers of the CNS is a premier open-access journal published by BMC, dedicated to advancing the field of neuroscience by exploring the complexities of the fluid dynamics and barriers of the central nervous system. Since its inception in 2011, the journal has established itself as a vital resource for researchers, professionals, and students alike, providing a platform for innovative research and critical discussions in areas such as cellular and molecular neuroscience, developmental neuroscience, neurology, and miscellaneous medicine. With an impressive Q1 ranking across multiple categories in 2023, and strong performance metrics such as being ranked in the 93rd percentile in Developmental Neuroscience, this journal not only highlights cutting-edge research but also contributes to the ongoing dialogue surrounding neurophysiology and pathology. As an open-access journal based in London, United Kingdom, it ensures that high-quality research is accessible to a global audience, fostering collaboration and knowledge-sharing in the neuroscientific community.

NEUROMOLECULAR MEDICINE, published by HUMANA PRESS INC, is a prestigious peer-reviewed journal dedicated to advancing the fields of cellular and molecular neuroscience, molecular medicine, and neurology. With an ISSN of 1535-1084 and an E-ISSN of 1559-1174, the journal boasts a significant presence in academic research since its inception in 2002 and continues to publish cutting-edge studies through 2024. Ranked in the Q2 category for 2023 in various disciplines, including Neuroscience and Molecular Medicine, it holds impressive positions in Scopus rankings, including 41st out of 192 in Neuroscience and Neurology. Although not an open access journal, NEUROMOLECULAR MEDICINE remains invaluable for researchers, professionals, and students seeking to explore the intricate relationships between molecular mechanisms and neurological functions, thereby contributing to the scientific understanding of nervous system diseases and therapeutic innovations.

Molecular Neurodegeneration is a leading journal published by BMC, dedicated to advancing the field of neurodegeneration through high-quality, open-access research. Since its inception in 2006, this peer-reviewed journal has provided a pivotal platform for the dissemination of innovative findings in the realms of Cellular and Molecular Neuroscience, Molecular Biology, and Clinical Neurology. With a stellar impact factor and listed in the prestigious Q1 category in multiple relevant categories, it ranks among the top publications in the field—specifically, it holds the #3 position in Neuroscience and #6 position in Clinical Neurology based on Scopus metrics. Researchers, professionals, and students alike will find significant value in the open access format, which fosters unrestricted sharing of knowledge, ensuring that emerging ideas in neurodegeneration reach a global audience. Based in London, United Kingdom, the journal promises a comprehensive scope that addresses critical questions in neurobiology, making it an essential resource for anyone interested in the molecular mechanisms underlying neurodegenerative diseases.

Neurology-Neuroimmunology & Neuroinflammation, published by LIPPINCOTT WILLIAMS & WILKINS, stands at the forefront of research in the rapidly evolving fields of neurology and neuroimmunology. Since its inception in 2014, this prestigious journal has embraced an Open Access model, ensuring that groundbreaking findings are readily available to researchers, clinicians, and students worldwide. Covering a broad spectrum of topics related to neuroinflammation, the journal has gained a remarkable reputation, attaining a Q1 ranking in both Neurology and Neurology (clinical) as of 2023, and ranking #6 out of 192 in the neuroscience category on Scopus. The journal's commitment to high-quality research aims to facilitate the understanding of neurological disorders, promote innovative therapies, and inspire collaboration among professionals. Addressing critical issues at the intersection of neurology, immunology, and clinical practice, Neurology-Neuroimmunology & Neuroinflammation is an essential platform for the dissemination of knowledge and the advancement of this vital field.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.